Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alimta plus Gemcitabine in Advanced or Metastatic NSCLC
NCT00061451Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed in non-small cell lung cancer (NSCLC), sponsored by Eli Lilly and Company. Primary endpoint: Objective Tumor Response Rate. Started Dec 2002; status: completed.
02
Drugs
pemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00061451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00061451.